Argenica Therapeutics advances on positive data from brain stroke drug study

Argenica Therapeutics

30/03/2022 04:03

** Biotech firm Argenica Therapeutics Ltd  AGN.AX  rises as
much as 7.1% to A$0.60, posts biggest intraday pct jump since
Feb. 24
    ** Says https://wcsecure.weblink.com.au/pdf/AGN/02504192.pdf
 got positive results from a pre-clinical study assessing the
efficacy of ARG-007 - a neuroprotective peptide drug to treat
brain strokes
    ** Says study showed positive results on drug protecting
brain cells after blood flow disruption to brain, a condition
known as cerebral ischaemia
    ** Adds it will explore potential application of ARG-007 as
a neuroprotective therapeutic for global cerebral ischaemia;
consider ways to move research into clinical trials
    ** AGN at its highest since March 16; on track for a fourth
straight session of gains
    ** AGN down 32.9% this year, as of last close

 (Reporting by Sameer Manekar in Bengaluru)
 ((Sameer.Manekar@thomsonreuters.com; Twitter: https://twitter.com/sameer_manekar))